GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alterity Therapeutics Ltd (NAS:ATHE) » Definitions » EV-to-EBITDA

Alterity Therapeutics (Alterity Therapeutics) EV-to-EBITDA

: (As of Today)
View and export this data going back to 2002. Start your Free Trial

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Alterity Therapeutics's enterprise value is $17.94 Mil. Alterity Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 was $0.00 Mil. Therefore, Alterity Therapeutics's EV-to-EBITDA for today is .

The historical rank and industry rank for Alterity Therapeutics's EV-to-EBITDA or its related term are showing as below:

ATHE' s EV-to-EBITDA Range Over the Past 10 Years
Min: -69.15   Med: 0.96   Max: 2.44
Current: -1.88

During the past 13 years, the highest EV-to-EBITDA of Alterity Therapeutics was 2.44. The lowest was -69.15. And the median was 0.96.

ATHE's EV-to-EBITDA is ranked worse than
100% of 469 companies
in the Biotechnology industry
Industry Median: 9.16 vs ATHE: -1.88

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-19), Alterity Therapeutics's stock price is $2.04. Alterity Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was $-2.302. Therefore, Alterity Therapeutics's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Alterity Therapeutics EV-to-EBITDA Historical Data

The historical data trend for Alterity Therapeutics's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alterity Therapeutics Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
EV-to-EBITDA
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.92 -0.87 -2.07 0.23 -0.11

Alterity Therapeutics Quarterly Data
Dec17 Jun18 Dec18 Jun19 Sep19 Dec19 Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBITDA Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - -0.11 - -

Competitive Comparison

For the Biotechnology subindustry, Alterity Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alterity Therapeutics EV-to-EBITDA Distribution

For the Biotechnology industry and Healthcare sector, Alterity Therapeutics's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Alterity Therapeutics's EV-to-EBITDA falls into.



Alterity Therapeutics EV-to-EBITDA Calculation

Alterity Therapeutics's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=17.939/0
=

Alterity Therapeutics's current Enterprise Value is $17.94 Mil.
Alterity Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alterity Therapeutics  (NAS:ATHE) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Alterity Therapeutics's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=2.04/-2.302
=At Loss

Alterity Therapeutics's share price for today is $2.04.
Alterity Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.302.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Alterity Therapeutics EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Alterity Therapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Alterity Therapeutics (Alterity Therapeutics) Business Description

Traded in Other Exchanges
Address
350 Collins Street, Level 14, Melbourne, VIC, AUS, 3000
Alterity Therapeutics Ltd is active in the healthcare domain. The company is engaged in research collaborations for the treatment of Parkinsonian movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company's lead drug candidate-PBT2 is being developed for the treatment of Alzheimer's and Huntington's diseases. It has also advanced a drug candidate for Parkinson's disease and other movement disorders (ATH434). The Group operated in one segment, being researching and developing Parkinsonian and other neurodegenerative disorders.